/
GUTS
$0.80+$0.05 (+7.08%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$117.9M
159M shares
52-week range
$0.38 – $2.45
20% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.88%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-12.05
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $120.0K | $93.0K | $0 |
| Cost of revenue | $893.0K | $770.0K | $0 | $452.0K | $77.0K | $50.0K | $0 |
| Gross profit | −$893.0K | −$770.0K | $0 | −$452.0K | $43.0K | $43.0K | $0 |
| Gross margin | — | — | — | — | 35.8% | 46.2% | — |
| R&D | $20.9M | $22.4M | $26.4M | $34.4M | $38.0M | $70.5M | $74.5M |
| Operating income | −$29.9M | −$29.0M | −$36.9M | −$49.4M | −$50.8M | −$93.5M | −$96.8M |
| EBITDA | −$29.0M | −$28.2M | −$36.6M | −$46.0M | −$76.8M | −$68.0M | −$139.8M |
| Net income | −$30.6M | −$30.5M | −$38.7M | −$46.5M | −$77.1M | −$68.7M | −$141.0M |
| Net margin | — | — | — | — | -64242.5% | -73864.5% | — |
| EPS (diluted) | -0.64 | -0.86 | -1.12 | -1.34 | -1.98 | -1.62 | -1.86 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $12M | $-0.37 | $-0.43–$-0.33 | 4 |
| 2027 | $22M | $-0.53 | $-0.78–$-0.36 | 4 |
| 2028 | $92M | $-0.34 | $-0.37–$-0.31 | 2 |
| 2029 | $252M | $0.09 | $0.06–$0.14 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.24
Price
$0.80
Implied downside
-69%
Peer comparison
Fractyl Health, Inc. Common Stock
Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.
www.fractyl.com- Employees
- 73
- IPO / List date
- Feb 2, 2024
- HQ
- BURLINGTON, MA
Held by traders on TradeandTell
No one on the platform currently holds GUTS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 35,200 | $16.1K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded GUTS yet.
